VIR - Vir Biotechnology, Inc.

9.1
-0.460   -5.055%

Share volume: 2,457,741
Last Updated: 03-05-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.04%

PREVIOUS CLOSE
CHG
CHG%
$9.56
-0.46
-0.05%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
33%
Profitability 35%
Dept financing 23%
Liquidity 50%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-2.57%
1 Month
26.56%
3 Months
38.30%
6 Months
75.34%
1 Year
12.76%
2 Year
-1.09%
Key data
Stock price
$9.10
P/E Ratio 
0.00
DAY RANGE
$9.06 - $9.57
EPS 
-$3.13
52 WEEK RANGE
$4.16 - $10.94
52 WEEK CHANGE
$14.32
MARKET CAP 
838.924 M
YIELD 
N/A
SHARES OUTSTANDING 
139.517 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-01-2025
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$12,180,211
AVERAGE 30 VOLUME 
$6,097,926
Company detail
CEO: George A. Scangos
Region: US
Website: vir.bio
Employees: 580
IPO year: 2019
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs, for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health.

Recent news